Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Leukemia. Browse Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 23, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
5288
Shown on this page
12
Local recruiting
59
Local phase groups
5

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Leukemia studies are organized in the registry

“Leukemia” is an umbrella term; in practice most records name the specific subtype, and this directory has dedicated pages for the major ones — acute myeloid (AML), chronic lymphocytic (CLL), and acute lymphoblastic (ALL) leukemia. Use this page when scanning across subtypes, and the subtype pages when you know which disease you mean.

  • 63% of the 94 locally indexed Leukemia records are currently marked recruiting.
  • The most common phase group in the local index is Phase 2 (30 records).
  • The most frequent sponsor is Memorial Sloan Kettering Cancer Center (12 records).
  • The most listed study location is Boston, Massachusetts (27 records).
Terms that often appear in related listings
AML CLL ALL CML relapsed refractory

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Leukemia. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1–12 of 5,288 matching trials for Leukemia.
Live ClinicalTrials.gov results.

Phase distribution

Phase 2 30
Phase 1 30
Not applicable 19
Phase 3 2
Early Phase 1 2

Top locations

Boston, Massachusetts 27 New York, New York 22 Houston, Texas 21 Los Angeles, California 11 Chicago, Illinois 11 Seattle, Washington 11

Top sponsors

Memorial Sloan Kettering Cancer Center 12 Dana-Farber Cancer Institute 10 M.D. Anderson Cancer Center 8 UNC Lineberger Comprehensive Cancer Center 4 Children's Oncology Group 3 Massachusetts General Hospital 3

Top therapies

Venetoclax 10 Cyclophosphamide 8 Cytarabine 6 Rituximab 5 Fludarabine 4 Azacitidine 3

Live official records

Open in full search
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

NCT03114865
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic Leukaemia
Interventions
Blinatumomab 9ug, Blinatumomab 28 ug, Blinatumomab, Dexamethasone
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01886872
View directory record Official record
Conditions
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Bendamustine Hydrochloride, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rituximab
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
65 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
917
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 596 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

NCT01163357
View directory record Official record
Conditions
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
bortezomib, fludarabine phosphate, melphalan, total marrow irradiation, tacrolimus, sirolimus, peripheral blood stem cell transplantation, laboratory biomarker analysis
Drug · Other · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Natural History Study of Early Life Exposures in Agriculture (ELEA)

NCT07328516
View directory record Official record
Conditions
Prostate Cancer, Leukemia, Breast Cancer, Melanoma, Colorectal Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
64,277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT
Not yet recruiting No phase listed Observational

Real World Asparaginase Therapy Toxicity

NCT07008027
View directory record Official record
Conditions
Drug Toxicity
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT
Enrolling by invitation No phase listed Observational

Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies

NCT02473757
View directory record Official record
Conditions
Lyphoma, B-Cell, Leukemia, B-cell, Multiple Myeloma, Hematologic Malignancies
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

NCT02158091
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
IPI-145, Fludarabine, Cyclophosphamide, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT
Recruiting Phase 1 Interventional

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

NCT07012044
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Decitabine and Cedazuridine, Filgrastim, Imaging Procedure, Lumbar Puncture
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT
Recruiting Not applicable Interventional

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

NCT05621291
View directory record Official record
Conditions
B-All, Acute Lymphoblastic Leukemia
Interventions
NGS testing
Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT
Recruiting Phase 1 Interventional

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

NCT07572136
View directory record Official record
Conditions
B-All, Acute Lymphoblastic Leukemia
Interventions
TSLPR-CART, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT
Recruiting Phase 1 Interventional

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT06177067
View directory record Official record
Conditions
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions
Revumenib, Venetoclax, Azacitidine, intrathecal (IT) chemotherapy, Cytarabine, Methotrexate
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
San Diego, California • Aurora, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT
Recruiting Phase 1 Interventional

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

NCT06904066
View directory record Official record
Conditions
Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute
Interventions
aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500
Drug · Biological · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 4:47 AM EDT

About this Leukemia clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Leukemia.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Leukemia.